News Related to Premenstrual Syndrome

Related coverage linked through entity extraction aliases.

Immunic Presents New Phase 2 CALLIPER Data, Secures $400M for Vidofludimus Calcium

May 28, 2026

Immunic presented new Phase 2 CALLIPER data at CMSC 2026 showing vidofludimus calcium's favorable effects in progressive MS, including a novel unified disability endpoint. The company also secured $400M in private placement to fund Phase 3 ENSURE studies and commercial preparations.

Orphan Drug Designation Drives Rare Disease Therapy Development Across Global Markets

Mar 15, 2026

Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.